MyoKardia is a clinical stage biopharmaceutical company pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. Our initial focus: treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction.

- Founded in 2012 by world-class experts in cardiovascular disease, cardiac muscle biology and genetics—leaders in science and academia integral to the approval of significant new cardiovascular therapies.
- A clinical stage biopharmaceutical company applying advanced, precision medicine to treat heritable and rare cardiovascular diseases.
- Values-based culture led by experienced team with track record of success at the world’s most successful biotech and pharma companies.
- Global collaboration agreement with Sanofi in one of the largest research and development commitments to genetic cardiomyopathy.

“We feel a profound sense of responsibility to help patients by doing what we feel we are uniquely able to do: attain a deeper understanding of the underlying causes of these diseases to discover and develop potentially transformative therapies.”

Tassos Gianakakos
CEO, MyoKardia

Help us create and sustain a place where talented people can do the best work of their lives.

We are a growing community of employees who enjoy working with and learning from each other, and collaborating in a way that ensures the growth of the company as well each employee individually. MyoKardia is committed to creating a culture that’s centered on our core values. We seek individuals who not only offer expertise in their respective fields, but can serve as cultural leaders and role models for our values.

Interested in being considered for an open position?

Apply on MyoKardia’s career website:

Learn More: www.myokardia.com

Follow us on Twitter @MyoKardia and LinkedIn
Expected Pipeline Product Updates and Milestones 2016-2017

Our Hypertrophic Cardiomyopathy (HCM) and Dilated Cardiomyopathy (DCM) Research

- Top-line data from our Phase 1 single ascending dose study of MYK-461* in HCM patients (001 study) in the second quarter of 2016.
- Top-line data from our Phase 1 multiple ascending dose study of MYK-461 in healthy volunteers (003 study) by mid-year 2016.

- We expect to initiate Phase 2 clinical development for MYK-461 in HCM patients in the second half of 2016.
- We plan to initiate Phase 1 clinical development for our DCM-1 product candidate in the first half of 2017.

*MYK-461 is an orally administered small molecule that reduces left ventricular contractility. MYK-461 is the subject of three Phase 1 clinical trials, which have been primarily designed to evaluate safety and tolerability of oral doses of MYK-461 and are expected to provide data on its pharmacokinetic and pharmacodynamics profile. These studies assess MYK-461’s engagement of cardiac myosin by measuring reduction in cardiac muscle contractility via echocardiography.

The SHaRe Registry

The Sarcomeric Human Cardiomyopathy Registry, or SHaRe, is a cornerstone of our precision medicine platform. SHaRe is multi-center, international repository of clinical and laboratory data on individuals and families with genetic heart disease.

SHaRe is a collaboration with several cardiovascular centers of excellence.

THE AMERICAS

- Boston Children's Hospital
- Brigham and Women's Hospital
- Cincinnati Children’s Hospital
- Stanford University Medical Center
- University of Michigan Medical Center
- University of Sao Paulo, Brazil
- Yale–New Haven Hospital

EUROPE

- Akureyri Hospital, Iceland
- Erasmus University Medical Center, The Netherlands
- Florence Centre for Cardiomyopathies, Italy
- Royal Brompton Hospital, London
- The Heart Hospital, University College, London

CONTACT

MyoKardia, Inc.
333 Allerton Avenue
South San Francisco, CA 94080
(650) 741-0900 or IR@MyoKardia.com
www.myokardia.com

MyoKardia is traded on the NASDAQ Global Market, ticker symbol MYOK